Joseph E. Gilliam Sells 2,500 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOSGet Free Report) COO Joseph E. Gilliam sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $113.50, for a total value of $283,750.00. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $11,559,407.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Glaukos Trading Down 0.7 %

GKOS stock opened at $113.96 on Friday. The company has a market cap of $5.74 billion, a price-to-earnings ratio of -39.57 and a beta of 1.09. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. The business has a fifty day simple moving average of $103.30 and a 200-day simple moving average of $90.06. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $115.78.

Glaukos (NYSE:GKOSGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The firm had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The company’s quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.59) earnings per share. On average, equities research analysts expect that Glaukos Co. will post -2.26 EPS for the current year.

Institutional Trading of Glaukos

A number of institutional investors and hedge funds have recently made changes to their positions in GKOS. National Bank of Canada FI acquired a new stake in shares of Glaukos during the 4th quarter worth $46,000. GAMMA Investing LLC acquired a new stake in Glaukos in the 4th quarter valued at $55,000. Quadrant Capital Group LLC increased its holdings in Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. increased its holdings in Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after purchasing an additional 1,465 shares in the last quarter. Finally, Cetera Advisors LLC acquired a new stake in Glaukos in the 1st quarter valued at $213,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of recent research reports. Mizuho upped their target price on Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. upped their target price on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Truist Financial reaffirmed a “buy” rating and issued a $125.00 target price (up previously from $120.00) on shares of Glaukos in a research note on Thursday, May 2nd. Citigroup increased their price target on Glaukos from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Finally, Wells Fargo & Company increased their price target on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and an average price target of $112.27.

Read Our Latest Report on GKOS

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Further Reading

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.